Trial Profile
Impact of Eculizumab treatment on extracellular vesicles pathophysiology of thrombosis in patients with Paroxysmal Nocturnal Hemoglobinuria: an open label, longitudinal, pilot, prospective study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2018
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- 20 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association